Antioxidants in Kidney Diseases : The Impact of Bardoxolone Methyl

Abstract EN

Drugs targeting the renin-angiotensin-aldosterone system (RAAS) are the mainstay of therapy to retard the progression of proteinuric chronic kidney disease (CKD) such as diabetic nephropathy.

However, diabetic nephropathy is still the first cause of end-stage renal disease.

New drugs targeted to the pathogenesis and mechanisms of progression of these diseases beyond RAAS inhibition are needed.

There is solid experimental evidence of a key role of oxidative stress and its interrelation with inflammation on renal damage.

However, randomized and well-powered trials on these agents in CKD are scarce.

We now review the biological bases of oxidative stress and its role in kidney diseases, with focus on diabetic nephropathy, as well as the role of the Keap1-Nrf2 pathway and recent clinical trials targeting this pathway with bardoxolone methyl.